Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
If a patient with limited scleroderma presents with the three active domains including skin thickening, inflammatory joint pain, and ILD would you consider starting Actemra?
Related Questions
Would you continue belimumab in high risk lupus patients with overlapping scleroderma features with ILD who become pregnant and who are already on HCQ and azathioprine?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
How do you envision incorporating CAR-T therapy into your clinical practice?
What Barrett's Esophagus screening protocol do you follow for patients with scleroderma given the increased risk of reflux and esophageal stasis?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
What is your approach to a patient with generalized morphea, no systemic involvement but a positive RNA Polymerase III?
